
Vapitadine (Barrier Therapeutics) is an investigational oral antihistamine that belongs to a new structural class of H1-selective, nonsedating agents. Results of a randomized, placebo-controlled clinical trial in adults with atopic dermatitis demonstrated its efficacy for relieving itch and added to an existing database showing vapitadine has an excellent safety profile.